ethyl 7-bromo-1-oxo-2,3-dihydro-1H-pyrrolo[1,2-a]indole-2-carboxylate | 1202766-27-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 7-bromo-1-oxo-2,3-dihydro-1H-pyrrolo[1,2-a]indole-2-carboxylate
• 英文别名: Ethyl 6-bromo-3-oxo-1,2-dihydropyrrolo[1,2-a]indole-2-carboxylate
• CAS: 1202766-27-5
• 化学式: C₁₄H₁₂BrNO₃
• 分子量: 322.158
• InChiKey: CRQDMZXSIARAKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  48.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 7-bromo-1-oxo-2,3-dihydro-1H-pyrrolo[1,2-a]indole-2-carboxylate 在 水 、 溶剂黄146 作用下， 反应 27.0h， 生成 7-bromo-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-one
  参考文献：
  名称：

  [EN] ALKYNYL ALCOHOLS AS KINASE INHIBITORS
  [FR] ALCOOLS D'ALCYNYLE UTILISÉS COMME INHIBITEURS DE KINASES

  摘要：

  选定的化合物对预防和治疗炎症和炎症性疾病，如NIK介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药及其药用可接受的盐，以及用于预防和治疗涉及炎症等疾病和其他疾病或病症的药物组合物和方法。

  公开号：

  WO2009158011A1
• 作为产物：
  描述：

  5-溴吲哚-2-羧酸乙酯 、 丙烯酸丁酯 在 sodium hydride 作用下， 生成 ethyl 7-bromo-1-oxo-2,3-dihydro-1H-pyrrolo[1,2-a]indole-2-carboxylate
  参考文献：
  名称：

  Fused tricyclic indoles as S1P1 agonists with robust efficacy in animal models of autoimmune disease

  摘要：

  Two series of fused tricyclic indoles were identified as potent and selective S1P(1) agonists. In vivo these agonists produced a significant reduction in circulating lymphocytes which translated into robust efficacy in several rodent models of autoimmune disease. Importantly, these agonists were devoid of any activity at the S1P(3) receptor in vitro, and correspondingly did not produce S1P(3) mediated bradycardia in telemeterized rat. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.129

文献信息

• [EN] ALKYNYL ALCOHOLS AS KINASE INHIBITORS<br/>[FR] ALCOOLS D'ALCYNYLE UTILISÉS COMME INHIBITEURS DE KINASES
  申请人：AMGEN INC

  公开号：WO2009158011A1

  公开（公告）日：2009-12-30

  Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like.

  选定的化合物对预防和治疗炎症和炎症性疾病，如NIK介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药及其药用可接受的盐，以及用于预防和治疗涉及炎症等疾病和其他疾病或病症的药物组合物和方法。
• ALKYNYL ALCOHOLS AS KINASE INHIBITORS
  申请人：Chen Guoqing

  公开号：US20110086834A1

  公开（公告）日：2011-04-14

  Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like.

  所选化合物对于预防和治疗炎症和炎症性疾病（如NIK介导的疾病）有效。本发明涵盖新的化合物、类似物、前药和其药学上可接受的盐、制药组合物和预防和治疗涉及炎症等疾病和其他疾病或病症的方法。
• Fused tricyclic indoles as S1P1 agonists with robust efficacy in animal models of autoimmune disease
  作者：Daniel J. Buzard、Sangdon Han、Luis Lopez、Andrew Kawasaki、Jeanne Moody、Lars Thoresen、Brett Ullman、Juerg Lehmann、Imelda Calderon、Xiuwen Zhu、Tawfik Gharbaoui、Dipanjan Sengupta、Ashwin Krishnan、Yinghong Gao、Jeff Edwards、Jeremy Barden、Michael Morgan、Khawja Usmani、Chuan Chen、Abu Sadeque、Jayant Thatte、Michelle Solomon、Lixia Fu、Kevin Whelan、Ling Liu、Hussien Al-Shamma、Joel Gatlin、Minh Le、Charles Xing、Sheryll Espinola、Robert M. Jones

  DOI：10.1016/j.bmcl.2012.04.129

  日期：2012.7

  Two series of fused tricyclic indoles were identified as potent and selective S1P(1) agonists. In vivo these agonists produced a significant reduction in circulating lymphocytes which translated into robust efficacy in several rodent models of autoimmune disease. Importantly, these agonists were devoid of any activity at the S1P(3) receptor in vitro, and correspondingly did not produce S1P(3) mediated bradycardia in telemeterized rat. (C) 2012 Elsevier Ltd. All rights reserved.